Results 141 to 150 of about 61,057 (265)

Ectopic Adipocytes in Scarring Alopecias: Comparison With Normal Scalp and Potential Therapeutic Implications

Journal of Cutaneous Pathology, EarlyView.
Annelise de Almeida Verdolin, Nadia El Kadi, Leonard Sperling, Luciana Pantaleão, Maria Fernanda Reis Gavazzoni Dias   +4 more
wiley   +1 more source

Minimal Disease Activity as A New Therapeutic Target in Atopic Dermatitis: A 5‐Year Real‐Life Experience With Dupilumab

International Journal of Dermatology, EarlyView.
ABSTRACT Background Atopic dermatitis (AD) is a chronic inflammatory skin disease with significant physical and psychosocial burden. Dupilumab, a monoclonal antibody targeting IL‐4Rα, has proven to be effective for moderate‐to‐severe AD, but long‐term real‐world data remain limited.
Francesco Leo, Luca Mastorino, Luca Cangialosi, Davide Favre, Chiara Anna Fiasconaro, Yingying Liao, Federico Goso, Niccolò Siliquini, Giovanni Cavaliere, Pietro Quaglino, Simone Ribero, Michela Ortoncelli   +11 more
wiley   +1 more source

Alopecia areata during dupilumab therapy: 2 cases and review of the literature. [PDF]

JAAD Case Rep
Almulhim AN, Alotaibi HK, Alfehaid SM, Albaker JW, Almakhaitah S, Shaikh LY.   +5 more
europepmc   +1 more source

Epidemiology, Diagnosis and Management of Alopecia Areata: An Asia‐Pacific Modified Delphi Expert Panel Recommendations

International Journal of Dermatology, EarlyView.
A panel of 18 dermatologists participated in a three‐round Delphi‐based consensus process to generate a standardized framework for the diagnosis and management of alopecia areata (AA) in Asia Pacific. Recommendations focus on practicality and clinical relevance within the regional context.
Rodney Sinclair, Chao‐Chun Yang, Wen‐Hung Chung, Rachita Dhurat, Anil Ganjoo, Saranya Khunkhet, Jinran Lin, Anchala Parthasaradhi, Hyun‐Tae Shin, Kihyuk Shin, Poonkiat Suchonwanit, Kian Teo Tan, Jyh Jong Tang, Wenyu Wu, Felix Boon‐Bin Yap, Leona Yip, Angeline Yong, Cheng Zhou   +17 more
wiley   +1 more source

Public Interest in Janus Kinase (JAK) Inhibitors for Alopecia Areata: A Google Trend Analysis. [PDF]

JMIR Dermatol
Howard J, Kamili NAH, Idris H, Krueger LD.   +3 more
europepmc   +1 more source

Retrospective Evaluation of the Impact of the COVID-19 Pandemic on the Incidence of Alopecia Areata in a Single Dermatological Department. [PDF]

J Clin Med
Chętko Ł, Hofmann J, Brzychcy K, Matych M, Sobolewska-Sztychny D, Noweta M, Zakrzewski B, Dominiak M, Narbutt J, Lesiak A.   +9 more
europepmc   +1 more source

Scalp Microbiome Alterations in Androgenetic Alopecia: Patterns and Emerging Mechanistic Insights

International Journal of Dermatology, EarlyView.
Summary of the microbiome‐lipid‐microinflammation axis in androgenetic alopecia (AGA). Altered sebaceous gland activity, shifts in microbial abundance on the scalp and hair follicle, and follicular microinflammation interact bidirectionally, each reinforcing the others.
Aditya K. Gupta, Elizabeth M. Teasell, Amanda Liddy, Vasiliki Economopoulos   +3 more
wiley   +1 more source

The Gut Microbiome as a Therapeutic Target in Alopecia Areata: Not Yet Part of the Patient Treatment Plan

International Journal of Dermatology, EarlyView.
ABSTRACT Interest in the gut microbiome as a therapeutic target for treating alopecia areata (AA) has grown considerably. However, existing evidence remains limited and inconsistent. Currently, there is insufficient evidence to recommend microbiome‐directed testing and therapies to patients with AA.
Eric McMullen, Deema Abdel Hafeez, Nikhil Pai, Laurence Mainville, Shireen Dumont, Narachai Julanon, Romy Shenderey, Grace Xiong, Shahnawaz Towheed, Jeffrey Donovan   +9 more
wiley   +1 more source

Mechanism-Based Strategies for Prevention of Taxane-Induced Hair Follicle Damage in Cancer Chemotherapy. [PDF]

Cancers (Basel)
Amaya C, Schlumbrecht MP, Wikramanayake TC, Xu XX.   +3 more
europepmc   +1 more source

Early On‐Treatment Change in SALT as a Pragmatic Predictor of Ritlecitinib Response in Moderate‐To‐Severe Alopecia Areata: A Real‐World Cohort Study

International Journal of Dermatology, EarlyView.
Ritlecitinib induced rapid clinical improvement in moderate‐to‐severe alopecia areata in real‐world practice. Early change in SALT at Week 12 strongly discriminated Week‐24 responders, supporting a pragmatic treat‐to‐target checkpoint, alongside improvements in clinician‐reported and patient‐reported outcomes and a favorable safety profile.
Giuseppe Gallo, Isotta Giunipero di Corteranzo, Pietro Quaglino, Simone Ribero, Francois Rosset   +4 more
wiley   +1 more source